Studies have demonstrated that AXL expression is associated with antiangiogenic resistance, while the combination of AXL inhibitors with antiangiogenic agents could reduce vessel density in renal cell carcinoma patient-derived xenografts [109–111]. The gene discussed is AXL; the disease is hereditary clear cell renal cell carcinoma.